Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 139 Cr.
- Current Price ₹ 13.0
- High / Low ₹ 24.9 / 10.3
- Stock P/E 170
- Book Value ₹ 6.06
- Dividend Yield 0.00 %
- ROCE 4.19 %
- ROE 1.52 %
- Face Value ₹ 2.00
Pros
- Debtor days have improved from 221 to 172 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.5% over past five years.
- Promoter holding is low: 26.3%
- Company has a low return on equity of 6.31% over last 3 years.
- Earnings include an other income of Rs.3.21 Cr.
- Company has high debtors of 172 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
120.71 | 94.56 | 66.71 | 63.97 | 67.76 | 75.09 | 60.09 | 53.77 | 75.82 | 69.66 | 86.28 | 99.03 | |
118.23 | 94.85 | 66.16 | 60.49 | 64.97 | 73.01 | 59.18 | 51.12 | 68.94 | 60.28 | 84.61 | 98.95 | |
Operating Profit | 2.48 | -0.29 | 0.55 | 3.48 | 2.79 | 2.08 | 0.91 | 2.65 | 6.88 | 9.38 | 1.67 | 0.08 |
OPM % | 2.05% | -0.31% | 0.82% | 5.44% | 4.12% | 2.77% | 1.51% | 4.93% | 9.07% | 13.47% | 1.94% | 0.08% |
0.86 | 4.26 | 3.18 | 0.93 | 1.66 | 1.98 | 2.17 | 1.81 | 1.79 | 2.23 | 2.03 | 3.21 | |
Interest | 2.68 | 3.37 | 3.37 | 3.10 | 2.85 | 2.66 | 2.56 | 2.63 | 2.49 | 2.26 | 2.27 | 1.58 |
Depreciation | 0.04 | 0.45 | 0.37 | 0.28 | 0.25 | 0.27 | 0.44 | 0.43 | 0.46 | 0.50 | 0.51 | 0.49 |
Profit before tax | 0.62 | 0.15 | -0.01 | 1.03 | 1.35 | 1.13 | 0.08 | 1.40 | 5.72 | 8.85 | 0.92 | 1.22 |
Tax % | 50.00% | -6.67% | 300.00% | 32.04% | 40.74% | 37.17% | 62.50% | 25.71% | 29.72% | 25.31% | 22.83% | 33.61% |
0.30 | 0.16 | -0.03 | 0.71 | 0.80 | 0.71 | 0.03 | 1.05 | 4.02 | 6.60 | 0.72 | 0.82 | |
EPS in Rs | 0.38 | 0.20 | -0.04 | 0.15 | 0.08 | 0.07 | 0.00 | 0.10 | 0.38 | 0.63 | 0.07 | 0.08 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 11% |
3 Years: | 9% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 94% |
3 Years: | -41% |
TTM: | 14% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 24% |
3 Years: | 16% |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 8% |
3 Years: | 6% |
Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.50 | 0.50 | 0.50 | 3.00 | 6.59 | 6.59 | 10.55 | 10.55 | 10.55 | 10.55 | 10.72 | 26.09 |
Reserves | 2.57 | 2.74 | 2.70 | 0.97 | 14.01 | 14.81 | 10.84 | 11.87 | 15.81 | 29.99 | 32.12 | 38.82 |
18.77 | 25.09 | 21.04 | 22.86 | 18.40 | 17.07 | 17.04 | 17.85 | 20.81 | 14.73 | 13.49 | 12.32 | |
31.59 | 17.47 | 25.17 | 18.04 | 25.22 | 30.28 | 27.77 | 45.85 | 34.45 | 23.63 | 23.62 | 32.61 | |
Total Liabilities | 53.43 | 45.80 | 49.41 | 44.87 | 64.22 | 68.75 | 66.20 | 86.12 | 81.62 | 78.90 | 79.95 | 109.84 |
0.25 | 1.68 | 1.40 | 1.29 | 1.26 | 1.34 | 1.49 | 1.22 | 1.18 | 1.98 | 1.52 | 2.08 | |
CWIP | 0.36 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.08 | 0.05 | 0.49 | 0.67 | 0.74 | 0.00 |
Investments | 0.17 | 0.38 | 0.38 | 0.38 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 |
52.65 | 43.74 | 47.63 | 43.20 | 62.45 | 66.94 | 64.20 | 84.42 | 79.52 | 75.82 | 77.26 | 107.33 | |
Total Assets | 53.43 | 45.80 | 49.41 | 44.87 | 64.22 | 68.75 | 66.20 | 86.12 | 81.62 | 78.90 | 79.95 | 109.84 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-7.04 | -3.72 | 4.59 | 0.46 | -9.46 | 4.31 | 3.22 | 2.01 | 1.32 | 1.08 | 0.81 | -18.04 | |
-0.24 | 1.78 | 3.07 | 0.69 | 1.06 | -0.28 | -0.02 | -0.11 | -0.85 | 0.28 | 1.20 | -0.19 | |
6.49 | 1.93 | -7.62 | -1.20 | 8.50 | -3.99 | -3.14 | -1.81 | 0.42 | -1.73 | -1.42 | 18.49 | |
Net Cash Flow | -0.79 | 0.00 | 0.04 | -0.05 | 0.10 | 0.04 | 0.06 | 0.09 | 0.89 | -0.37 | 0.59 | 0.26 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 115.51 | 132.63 | 221.16 | 213.80 | 240.14 | 240.22 | 285.67 | 452.97 | 281.67 | 280.90 | 209.11 | 172.20 |
Inventory Days | 26.04 | 13.28 | 19.77 | 7.48 | 11.39 | 5.21 | 6.29 | 4.67 | 3.62 | 20.36 | 1.86 | 20.49 |
Days Payable | 98.99 | 65.64 | 144.63 | 99.98 | 136.37 | 130.38 | 168.82 | 320.63 | 163.13 | 120.15 | 95.10 | 115.63 |
Cash Conversion Cycle | 42.56 | 80.27 | 96.29 | 121.29 | 115.16 | 115.05 | 123.14 | 137.01 | 122.16 | 181.11 | 115.87 | 77.06 |
Working Capital Days | 58.54 | 97.81 | 109.10 | 114.97 | 177.17 | 153.70 | 195.77 | 238.60 | 196.41 | 252.82 | 209.49 | 259.07 |
ROCE % | 19.29% | 14.03% | 12.78% | 16.17% | 12.76% | 9.78% | 6.87% | 10.24% | 18.78% | 21.69% | 5.72% | 4.19% |
Documents
Announcements
-
Copy of Newspaper Publication
31 May 2025 - Vaishali Pharma publishes audited financial results for FY ended 31 March 2025 as per SEBI regulations.
-
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
28 May 2025 - VAISHALI PHARMA LIMITED has informed about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Outcome of Board Meeting
28 May 2025 - Board approved audited financial results for FY ended March 31, 2025.
-
Outcome of Board Meeting
28 May 2025 - Approved FY25 audited results; appointed secretarial auditor for 5 years, subject to member approval.
-
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
24 May 2025 - VAISHALI PHARMA LIMITED has informed about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
May 2020TranscriptNotesPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations